As­traZeneca's Covid-19 an­ti­body cock­tail miss­es the mark in pre­vent­ing symp­toms post-ex­po­sure

As the field for mon­o­clon­al an­ti­body treat­ments of Covid-19 grows more crowd­ed, As­traZeneca has an­nounced a study of its own cock­tail AZD7442 did not meet its main goal of pre­vent­ing symp­to­matic Covid-19.

The com­pa­ny’s long-act­ing an­ti­body com­bo was used in a tri­al with un­vac­ci­nat­ed adults about the age of 18 with con­firmed ex­po­sure. AZD7442 re­duced the risk by just 33%, a fig­ure that was not sta­tis­ti­cal­ly sig­nif­i­cant.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER